每经AI快讯，京新药业（SZ 002020，收盘价：19.64元）10月10日晚间发布公告称，公司第九届第一次 董事会会议于2025年10月10日在公司行政楼一楼会议室召开。会议审议了《关于选举第九届董事会各专 业委员会委员的议案》等文件。 每经头条（nbdtoutiao）——天水麻辣烫、淄博烧烤、荣昌卤鹅⋯⋯"泼天流量"退去后，这些城市怎么 样了？ （记者 王晓波） 截至发稿，京新药业市值为169亿元。 2025年1至6月份，京新药业的营业收入构成为：成品药占比58.28%，原料药占比22.44%，医用器械占 比17.32%，其他业务占比1.95%。 ...

每经AI快讯，京新药业（SZ 002020，收盘价：20.28元）10月9日晚间发布公告称，截至2025年9月30 日，公司通过股份回购专用证券账户以集中竞价方式回购公司股份约4727.13万股，占公司目前总股本 的5.49%，购买股份最高成交价为14.41元/股，购买股份最低成交价为11.86元/股，成交总金额约为6.09 亿元。 截至发稿，京新药业市值为175亿元。 每经头条（nbdtoutiao）——与美元脱钩后，暴涨102倍，揭秘黄金疯涨背后神秘的"无形之手"！专家： 推动金价上涨的逻辑没有变 2025年1至6月份，京新药业的营业收入构成为：成品药占比58.28%，原料药占比22.44%，医用器械占 比17.32%，其他业务占比1.95%。 （记者 曾健辉） ...

每经头条（nbdtoutiao）——重磅解读！中国将不寻求WTO新的特殊和差别待遇，意味着什么？ （记者 曾健辉） 每经AI快讯，京新药业（SZ 002020，收盘价：19.66元）9月29日晚间发布公告称，公司第八届第十八 次董事会会议于2025年9月29日以电话及传真方式召开。会议审议了《关于提请股东会授权董事会办理 第四期员工持股计划相关事宜的议案》等文件。 2025年1至6月份，京新药业的营业收入构成为：成品药占比58.28%，原料药占比22.44%，医用器械占 比17.32%，其他业务占比1.95%。 截至发稿，京新药业市值为169亿元。 ...

Group 1 - The company, Jingxin Pharmaceutical, announced the convening of its 17th board meeting on September 24, 2025, to review governance system proposals [1] - For the first half of 2025, Jingxin Pharmaceutical's revenue composition was as follows: finished drugs accounted for 58.28%, raw materials for 22.44%, medical devices for 17.32%, and other businesses for 1.95% [1] - As of the report date, Jingxin Pharmaceutical's market capitalization was 18.6 billion yuan [1]

Core Viewpoint - The chairman of Kelun Pharmaceutical, Liu Gexin, has become a spokesperson for the company's products, showcasing his physique in a recent advertisement, which has garnered significant attention on social media [4][5]. Financial Performance - In 2024, Kelun Pharmaceutical achieved a revenue of 21.812 billion yuan, representing a year-on-year growth of 1.67%, and a net profit of 2.936 billion yuan, up 19.53%, both hitting historical highs [1][7]. - From 2021 to 2023, the company's revenue grew from 17.277 billion yuan to 21.454 billion yuan, with respective year-on-year growth rates of 4.94%, 9.46%, and 12.69% [7]. - The sales expenses for Kelun Pharmaceutical have decreased for three consecutive years, from 4.728 billion yuan in 2022 to 3.493 billion yuan in 2024, with changes of -5.86%, -5.89%, and -21.51% respectively [1][10]. Research and Development - Kelun Pharmaceutical has invested nearly 14.5 billion yuan in R&D since 2013, with R&D expenses increasing from 1.795 billion yuan in 2022 to 2.171 billion yuan in 2024, reflecting growth rates of 3.37%, 8.27%, and 11.68% [2][8]. - The company has a diverse product portfolio, with 684 varieties and 1,073 specifications of pharmaceutical products, including 143 varieties of infusion products [9]. Market Position and Strategy - Kelun Pharmaceutical is recognized as one of the largest pharmaceutical enterprises in China, with a comprehensive industry system spanning R&D, manufacturing, and distribution [3]. - The company is focusing on optimizing its infusion product structure and expanding its market coverage, benefiting from national drug procurement policies [8][10]. - Analysts express optimism about Kelun Pharmaceutical's innovative drug business contributing significant revenue in 2025, despite short-term pressures on its infusion business [11]. Dividend Policy - For the fiscal year 2024, Kelun Pharmaceutical plans to distribute a total dividend of 1.214 billion yuan, which accounts for 41.34% of its net profit [10].